AR230-r
(ATCC® CRL-3346™)
Organism Homo sapiens, human
Tissuebone marrow; derived from metastatic site: pleural effusion
Product Format提供形式 frozen 1.0 mL
Morphology hematopoietic
Culture Properties suspension
Biosafety Level1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Diseasechronic myeloid leukemia in blast crisis
Age 年龄 52
Gender 性别 female
Applications This is a clone of the parental AR230 cell line which is resistant to the tyrosine kinase inhibitor imatinib mesylate, and is paired to the AR230-s clone which is resistant to imatinib. The paired AR230-s and AR230-r clones are useful cell line models of sensitivity and resistance to a tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia.
Storage Conditions liquid nitrogen vapor phase
Karyotype 44, XX, -11, -14, -17, -17, +mar, inv(1)(p31-32p36) or add(1)(p31-32), -2 or add(2)(p13), del(9)(q22) or der(9)t(9;?)(q11-13;?), der(9)t(9;?)(p13;?)t(9;22) (q34;q11), add(15)(p11), add(18)(q21), der(11;21)(q10;p10), der(22)t(9;22) (q34;q11), +der(22)t(9;22)(q34;q11)
ImagesCell Micrograph of AR230-r, ATCC CRL-3346
Derivation Erythroid-myeloid precursor cell line derived from chronic myelogenous leukemia at blast crisis
Clinical Data 52 years female
Oncogene BCR-ABL of the e19a2 fusion transcript type
Comments 注释 Chronic Myeloid Leukemia resistant to the tyrosine kinase inhibitor imatinib mesylate
Oncogenes: BCR-ABL of the e19a2 fusion transcript type
Erythroid-Myeloid precursor cell line derived from CML in blast crisis.
Complete Growth MediumThe complete medium for this cell line is RPMI-1640 + 10% FBS + 2 mM L-Glutamine + 1 μM Imatinib Details for preparation of 500 ml of complete media
Medium: 500 mL RPMI-1640 (ATCC 30-2001)
Serum: 56 mL FBS (ATCC 30-2020)
Additive: 5.6 mL L-Glutamine (200 mM, ATCC 30-2214)
0.5 mL 1 mM Imatinib working stock (see below)
To prepare 1 mM Imatinib working stock, aseptically combine the following:
25 mg Imatinib (Sigma catalog # CDS022173-25MG) into 45 mL Culture grade water (Hyclone catalog # SH30529
Note 注释 : Supplement Imatinib at each reseed rather than including in culture medium bottle. The shelf life for Imatinib in culture medium is unknown, so do not use a prepared culture medium bottle for more than 30 days. Additionally, if cell growth appears to slow during cell line expansion, prepare a new bottle of fresh medium.
Subculturing Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2.5 to 3.5 X 105 cells/mL and maintain between 2 X 105 and 1X 106 cells/mL.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density).
Culture Conditions
Atmosphere 需氧情况: air, 95%; carbon dioxide (CO2), 5%
Temperature 培养温度: 37°C
Volume容量 1.0 mL
STR Profile Amelogenin: X
CSF1PO: 10, 12
D13S317: 8, 10
D16S539: 9, 13
D5S818: 11, 13
D7S820: 10, 11
THO1: 6
TPOX: 11
vWA: 16, 20
Sterility TestsBacteria and Yeast: No growth
Mycoplasma: No growth
Population Doubling Time Approximately 30-48 hours
Name of Depositor 寄存人 J Vaz deMelo, University of Adelaide, Australia
Year of Origin收藏年份 1999
References 参考文献 Mahon FX, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96(3): 1070-1079, 2000 PubMed: 10910924
Wada H, et al. Establishment and molecular characterization of a novel leukemic cell line with Philadelphia chromosome expressing p230 BCR/ABL fusion protein. Cancer Res 55 (14): 3192-3196, 1995. PubMed: 7606740
Drexler HG, et al. Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia. Leuk Res 23 (3): 207-215, 1999. PubMed: 10071072